JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 3 filers reported holding JUNO THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,682,720,000 | +3.6% | 58,690 | +1.7% | 0.00% | 0.0% |
| Q3 2017 | $2,589,632,000 | +62.1% | 57,727 | +8.0% | 0.00% | 0.0% |
| Q2 2017 | $1,597,292,000 | +140.7% | 53,439 | +78.7% | 0.00% | +100.0% |
| Q1 2017 | $663,481,000 | +207237.8% | 29,900 | +76.4% | 0.00% | – |
| Q4 2016 | $320,000 | -69.9% | 16,953 | -52.2% | 0.00% | -100.0% |
| Q3 2016 | $1,064,000 | -21.9% | 35,464 | 0.0% | 0.00% | -50.0% |
| Q2 2016 | $1,363,000 | +84.4% | 35,464 | +82.8% | 0.00% | +100.0% |
| Q1 2016 | $739,000 | -87.6% | 19,400 | -85.7% | 0.00% | -85.7% |
| Q4 2015 | $5,955,000 | +33.5% | 135,422 | +23.6% | 0.01% | +40.0% |
| Q3 2015 | $4,460,000 | +29.7% | 109,598 | +70.0% | 0.01% | +66.7% |
| Q2 2015 | $3,439,000 | -13.4% | 64,481 | -1.5% | 0.00% | -25.0% |
| Q1 2015 | $3,970,000 | -21.9% | 65,450 | -32.8% | 0.00% | -20.0% |
| Q4 2014 | $5,086,000 | – | 97,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
| Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
| Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
| DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
| SIB LLC | 100,000 | $4,571,000 | 3.28% |
| PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
| Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
| ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
| BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
| Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |